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AbstrACt
Introduction In individuals with early (indexed ≤7 days 
poststroke) and severe upper limb paresis (shoulder 
abduction and finger extension score of <5 out of 10), 
our objectives are to: (1) determine if biomarkers of brain 
structure and function collected at <1 month poststroke 
explain who will experience clinically important recovery over 
the first 12 months poststroke; (2) compare stroke survivors’ 
perceptions of personally meaningful recovery to clinically 
important recovery; and (3) characterise the trajectory of 
change in measures of motor function, brain structure and 
function.
Methods and analysis Prospective observational study 
with an inception cohort of 78 first-time stroke survivors. 
Participants will be recruited from a single, large tertiary 
stroke referral centre. Clinical and biomarker assessments 
will be completed at four follow-up time points: 2 to 4 weeks 
and 3, 6 and 12 months poststroke. Our primary outcome 
is achievement of clinically important improvement on two 
out of three measures that span impairment (Fugl-Meyer 
Upper Limb, change ≥10 points), activity (Motor Assessment 
Scale item 6, change ≥1 point) and participation (Rating of 
Everyday Arm-use in the Community and Home, change 
≥1 point). Brain biomarkers of structure and function will 
be indexed using transcranial magnetic stimulation and 
MRI. Multilevel modelling will be performed to examine the 
relationship between clinically important recovery achieved 
(yes/no) and a priori defined brain biomarkers related to the 
corticospinal tract and corpus callosum. Secondary analyses 
will compare stroke survivor’s perception of recovery, as well 
as real-world arm use via accelerometry, to the proposed 
metric of clinically meaningful recovery; and model trajectory 
of recovery across clinical, a priori defined biomarkers and 
exploratory variables related to functional connectivity.
Ethics and dissemination Approved by the hospital and 
university ethics review boards. Results will be disseminated 
through peer-reviewed publications and conference 
presentations.
trial registration number NCT02464085.
IntroduCtIon 
Up to 30% of acute stroke patients have severe 
upper limb impairment.1 Clinical staff find it 
challenging to answer questions from patients 
such as ‘how much recovery might I expect to 
get back in my arm, how long will it take for 
me to recover, and will my recovery be mean-
ingful?’ Since people with early and severe 
impairment have a 50:50 chance of recovering 
some function versus not recovering,2 and clin-
ical measures have been found to add little 
to the ability to predict expected recovery,3 
answering these questions is difficult. The inad-
equacy of current clinical models to explain 
expected recovery was highlighted in the 
first international Stroke Rehabilitation and 
Recovery Roundtable biomarker consensus 
statement4 in which the need to develop and 
use biomarkers that relate to neurobiology and 
mechanisms of recovery to stratify or subgroup 
research participants in trials was a strong 
recommendation.
The most promising potential biomarkers 
for stratification of people with upper limb 
impairment (mild through to severe) relate 
strengths and limitations of the study
 ► Focused investigation of a neglected subgroup 
of stroke survivors with early, severe upper limb 
paresis.
 ► Clinical measures span the domains of the 
International Classification of Functioning, Disability 
and Health, and biomarkers span structural and 
functional methods.
 ► Data collection occurs at biologically relevant time 
points across the first year poststroke.
 ► Builds knowledge across the spectrum of clinical, 
biological and survivor perceptions of meaningful 
recovery.
 ► Findings from this single-centre inception cohort 
have the potential to inform clinical trial design ele-
ments of stratification and intervention timing.
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to the structure and function of the corticospinal tract 
(CST). The presence or absence of a motor-evoked poten-
tial (MEP+, MEP−) indexed using transcranial magnetic 
stimulation (TMS) captured from electromyography 
(EMG) of forearm musculature early after stroke (within 
7–10 days) explains initial Fugl-Meyer Upper Limb 
(FM-UL) outcome5 and predicts expected recovery.6 This 
biomarker is largely influenced by the structural integ-
rity and function of the CST. However, this dichotomised 
outcome (MEP+, MEP−) may not be sufficiently sensitive 
to meaningfully measure differences in the subgroup of 
individuals with severe upper limb impairment.
Here, we define severe upper limb impairment by the 
presence of early paresis of shoulder abduction and finger 
extension (SAFE) manual muscle test combined score 
of <5 out of a possible 10 points, which indicates little to no 
antigravity movement is possible. Our individual patient 
data review5 found that while MEP+ status was associated 
with better motor outcome in the severe subgroup, there 
was considerable variability in outcome scores (FM-UL) 
within the MEP+ and MEP− cohorts. Other studies have 
demonstrated that 15%–20% of individuals who are 
MEP− go on to experience some recovery.7–9
The contribution of other possible biomarkers that 
index CST have largely focused on neuroimaging 
methods. Information can be captured using anatom-
ical scans (T1) to identify overlap between the lesion 
and a mask of the CST,10 and diffusion tensor imaging 
to index (1) CST microstructural properties (eg, frac-
tional anisotropy (FA) to understand directionality), 
(2) FA asymmetry index (CST AI) between lesioned and 
unlesioned hemisphere11 or (3) tract number.12 These 
structural approaches concentrate on the impact of the 
lesion on the CST. Like MEP status, they are important 
when considering the spectrum of mild through to severe 
impairment.13 However, when focused on the subgroup 
with severe impairment, CST AI is not related to impair-
ment.5 13 This suggests that other factors may be important 
to explain expected recovery in the severe subgroup.
Inclusion of biomarkers beyond the CST may lead to 
enhanced models of recovery in individuals with severe 
motor impairment. For instance, corpus callosum 
(CC) white matter integrity using diffusion imaging 
appears to explain almost 50% of the variance in FM-UL 
outcome in this group.14 Other work has focused on 
the inter-relationships between the CST and other 
motor pathways using diffusion imaging, including the 
reticulospinal and premotor pathways to effect motor 
outcomes.15 Collectively, research into such alternative 
pathways has largely included people with chronic impair-
ment (>6 months poststroke); therefore, it is unknown if 
such regions are important early poststroke or represent 
compensatory regions relevant in the chronic phase.
Biomarkers of functional neuroimaging have received 
the least attention.4 A potential biomarker in the 
severe cohort is brain network activity measured with 
resting state functional MRI. As this approach can be 
used in patients with little to no movement poststroke 
to interrogate all brain networks simultaneously, it was 
defined as a developmental priority by the Stroke Reha-
bilitation and Recovery Roundtable consensus group.4 
Consistent with structural neuroimaging data that high-
light the importance of the CC, resting state functional 
connectivity in the early and late subacute phases shows 
that interhemispheric connectivity is of particular impor-
tance to motor recovery.10
Taken together, past work suggests that upper limb 
biomarkers are not one-size-fits-all.16 In the current 
paper, we detail the protocol for a longitudinal study 
that aims to link the neurobiology of human stroke to 
the observed trajectory of motor recovery, advancing 
current knowledge of upper limb recovery in people 
with severe impairment. Importantly, we will link our 
neurobiological and clinical findings to stroke survivor 
perspectives of what s/he considers to be meaningful 
recovery. This has not been addressed in any prior 
biomarker work. The findings of the current study can 
ultimately help determine the ‘right person’ to target 
and ‘right time’ for therapeutic intervention, as well as 
enabling more precise patient stratification of people 
with severe upper limb impairment poststroke in future 
trials.
The primary aim is to identify biomarker(s) of brain 
structure and/or function that explain which individ-
uals with severe upper limb paresis in the first 7 days 
poststroke will go on to experience clinically important 
recovery over the first 12 months poststroke. We hypoth-
esise that the CC will explain unique variance in recovery 
above and beyond the CST. Based on our prior work,5 13 14 
we expect the CST itself to explain negligible variation in 
people with severe impairment.
Secondary aims are to:
1. Describe, from the stroke survivor perspective, what 
is meaningful recovery, and understand when it is 
achieved over the first 12 months poststroke. We will also 
consider factors that might contribute to achievement, 
and how survivors’ perceptions of meaningful recov-
ery relate to our defined metric of clinically important 
recovery. We hypothesise that biomarker-defined clin-
ically important subgroups, will not be consistent with 
stroke survivors’ perceptions of personally meaningful 
recovery.
2. Characterise the trajectory of motor recovery across the 
International Classification for Functioning, Disability 
and Health (ICF) domains of impairment, activity, par-
ticipation and quality of life over the first 12 months 
poststroke. We hypothesise that most recovery will oc-
cur early rather than later poststroke, but there will be 
a subgroup of late recoverers.
3. Establish how brain structure and function change 
over the first 12 months poststroke using neuroimag-
ing and neurophysiological measures. We hypothesise 
that structural biomarkers will have a relatively flat 
trajectory throughout the first 12 months poststroke; 
however, functional biomarkers will show stronger tra-
jectories that are associated with motor recovery.
 o
n




pen: first published as 10.1136/bmjopen-2018-026435 on 25 November 2018. Downloaded from 




A prospective observational study of an inception 
cohort of individuals with severe upper limb paresis 
indexed ≤7 days poststroke (baseline) and followed up 
at four time points over the first 12 months poststroke. 
Follow-up time points (+/−2 weeks) are both clinically 
and biologically relevant:
 ► 2–4 weeks, stabilisation of acute changes17 ;
 ► 3 months, heightened window of plasticity presumed 
to taper18 and reflect end of early subacute recovery 
phase19 ;
 ► 6 months, end of late subacute recovery phase19; and
 ► 12 months, functional stabilisation.20
Participants and study sites
Patients who had a stroke and are admitted to a tertiary 
stroke referral centre in British Columbia Canada will be 
screened for eligibility. Approximately 600 patients with 
stroke are admitted annually. Stroke will be confirmed 
by medical practitioner diagnosis using CT or MRI scans 
at the recruiting centre. Patients deemed potentially 
eligible will continue to be screened until they either 
meet eligibility criteria, or are ineligible. Participants will 
be followed at two rehabilitation centres in Vancouver 
British Columbia Canada; all participants outside these 
catchment centres will be ineligible.
Patients will be eligible to participate if they are an adult 
(aged 18 to 90 years old) with severe upper limb paresis 
(SAFE score <5/10) ≤7 days following first clinically 
diagnosed stroke (ischaemic or haemorrhagic). Exclu-
sion criteria include another neurological condition, 
psychiatric illness, other medical condition(s) deemed 
to significantly limit function, palliative medical manage-
ment, insufficient communication and/or no access to an 
appropriate substitute decision maker (eg, carer, family) 
or interpreter.
recruitment
Patients deemed to fulfil all eligibility criteria will be invited 
to participate. Informed consent will be sought from the 
eligible patient or, if unable to provide written informed 
consent, an appropriate substitute decision maker will be 
approached to provide written consent. If English is their 
second language, we will ensure an appropriate translator 
or substitute decision maker is available. Once the patient 
gives informed consent, screening for TMS and MRI testing 
will be completed, demographic and baseline data collected 
and appropriate testing organised. Contraindication to 
either TMS or MRI precludes a patient from participating 
in the specific testing, but not the overall study. Demo-
graphic information (including age, sex, comorbidities) 
and stroke details (including stroke location, lesion type, 
use of thrombolysis/thrombectomy, admission and 24-hour 
National Institutes of Health Stroke Scale (NIHSS)) will 
be collated from the admission record or through patient 
interview,21 and participants will be asked to give consent to 
access routine clinical scan reports (CT and MRI).
outcomes
Dependent variable: clinically important recovery
The dependent variable is clinically important recovery. 
To date, there is no defined metric of clinically important 
recovery, nor a metric that encapsulates all ICF domains 
to describe recovery within a single outcome. There-
fore, for the purposes of this study, we define clinically 
important recovery as change of at least 15%–20% of the 
scale across two out of three upper limb measures that 
span ICF domains.22 The moment when a participant hits 
this benchmark on ANY two of these measures, they will 
be categorised as achieving clinically important change. 
The indices are:
 ► Impairment using the FM-UL: test comprises 33 
items rated from 0 to 2, where 0=cannot perform, 
1=performs partially, 2=performs fully, totalling 66 
points. This measure has good psychometric prop-
erties23 and has been recommended as a core data 
element by the Stroke Rehabilitation and Recovery 
Roundtable.21 A meaningful change for this outcome 
is defined as ≥10 points (15% change), which is 
consistent with past work of a clinically important 
change in motor impairment in the early stages of 
recovery.24
 ► Activity limitations using the Motor Assessment Scale 
items 6, 7 and 8 (MAS-UL): each item is rated out of 
a possible six points, leading to a possible 18 points 
in total. MAS6 measures upper arm function, MAS7 
measures hand movements and MAS8 measures 
advanced hand movements. This measure has good 
psychometric properties.25 A meaningful change is 
undefined, but it has been previously demonstrated 
that ≥1 point (15% change) on MAS6 reflects a shift 
in upper limb function ability.26 For the combined 
MAS-UL used in this study, a change of ≥3 points is 
required.
 ► Participation restriction of use of the arm in everyday 
life will be indexed using the Rating of Everyday 
Arm-use in the Community and Home (REACH): 
self-report measure of real-world task arm use 
completed via interview27 and rated out of a possible 
five points. Importantly, REACH indexes whether 
the stroke affected arm is a participant’s dominant 
or non-dominant arm. Meaningful change remains 
undefined on this measure, but in line with previous 
work, we adopted ≥1 point (15%) change.
Structural and functional brain measures
TMS will be used to characterise motor cortex excitability 
at rest and when active for the ipsilesional CST28 using 
a Magstim 2002 unit with a figure-8 coil. We will test a 
distal (extensor carpi radialis) and proximal (lateral head 
of triceps) muscle using standard protocols.28 29 Resting 
motor threshold will be defined as the percentage of stim-
ulator output intensity (%MSO) that elicits a MEP >50μV 
in 5 of 10 trials. Active motor threshold is the %MSO 
intensity that elicits a MEP >200μV in 5 of 10 trials while 
the participant holds a resisted contraction consistent with 
 o
n




pen: first published as 10.1136/bmjopen-2018-026435 on 25 November 2018. Downloaded from 
4 Hayward KS, et al. BMJ Open 2018;8:e026435. doi:10.1136/bmjopen-2018-026435
Open access 
the muscle of interest (wrist extension or elbow exten-
sion). Intensity of active muscle activity will be monitored 
real-time via EMG to ensure consistency. Breaks will be 
provided every 3–4 trials to ensure that fatigue does not 
influence performance. A trained therapist will provide 
resistance for all active movements. Participants will be 
characterised as MEP present (MEP+) or absent (MEP−) 
for both resting and active motor threshold testing of 
each muscle of interest. If a participant is MEP+, we will 
complete a recruitment curve (100%, 110%, 120%, 
130%, 140%, 150%) as able. If a participant is MEP−, we 
will characterise the number of trials a MEP was present 
per above criteria (out of 10) to afford serial probing in 
this cohort.
A MRI scan will be performed at 2–4 weeks and 3, 6 and 
12 months on a GE Discovery MR750 3T scanner using a 
32-channel head coil. We will collect both structural and 
functional sequences:
1. T1: 256FOV, 256×256 matrix, 1 mm slices, interleaved 
bottom up, scan duration ~5 min.
2. T2 Fluid-attenuated inversion recovery (FLAIR): TR 
9000 ms, TE 140 ms, TE2 90 ms, 256FOV, 256×256 ma-
trix, 3 mm slices, interleaved bottom up, scan dura-
tion ~5 min.
3. Diffusion tensor imaging (High Angular Resolution 
Diffusion Imaging (HARDI)): TR 7000 ms, TE mini-
mum, 73 slices, 2 mm thick, interleaved bottom up (60 
directions, b=1000), 3B0 interspersed throughout the 
sequence, scan duration ~7 min.
4. Resting state functional MRI: TR 2000 ms, TE 30 ms, 
150 samples, 3 mm slices with 1 mm spacing, inter-
leaved bottom up, two scan runs at 5 min each.
We will use the T1 and FLAIR scans in MRICRON to 
hand draw the stroke lesion and create a mask. Diffu-
sion tensor imaging will be processed in FMRIB Soft-
ware Library (FSL) and hand drawn regions of interest 
will be placed around the CST (using landmarks of the 
base of the corona radiata and anterior commissure30), 
and the CC (segmented into five regions31). Resting 
state sequences will be analysed to identify connectivity 
patterns.
Other outcomes
All measures will be collected at every follow-up time 
point, that is, 2–4 weeks and 3, 6 and 12 months post-
stroke. See table 1 for a list of outcomes and time points 
of collection.
Arm use will be measured using ActiGraph 3GTx 
accelerometers (ActiGraph, Florida, USA) that are worn 
for 7 consecutive days to quantify real-world arm use. 
Participants will be fitted with two accelerometers: less 
affected wrist and more affected wrist at each follow-up 
time point. Accelerometry data will be analysed using 
ActiLife software. Subsequent custom-built Matlab 
scripts will be used to describe mean upper limb use per 
day (hours), ratio of arm use per day (more affected: 
less affected hours), intensity of bilateral upper limb 
activity (bilateral magnitude) and the contribution of 
both upper limbs to activity (magnitude ratio) for each 
second of activity per day.32 Density plots will be used 
to examine each second of bilateral upper limb activity 
throughout a single day.
Quality of life will be indexed using the Stroke 
Impact Scale (SIS)33 and EuroQol-5 dimension-3 level 
(EQ-5D-3L).34 The SIS is a multidimensional self-re-
port measure of health status that includes 59 items to 
assess strength, hand function, activities of daily living, 
mobility, communication, emotion, memory, thinking 
and participation. EQ-5D, a brief measure of health-re-
lated quality of life, was added to the protocol following 
recommendation from the Stroke Rehabilitation and 
Recovery Roundtable.21 We will use the three-level 
option that has five domains on all participants post 
September 2017.
Stroke survivor perception of upper limb recovery will 
be examined using the Canadian Occupational Perfor-
mance Measure,35 Global Rating of Change scale36 and 
semistructured interviews. Semistructured interviews 
focus on three questions: (1) What is meaningful recovery 
to you; (2) Do you believe you have achieved meaningful 
recovery (yes/no, why); and (3) Do you still have hope 
for meaningful recovery (yes/no, why). These questions 
reflect themes related to recovery that were identified by 
previous qualitative research of individuals with upper 
limb impairment after stroke.37 38
Upper limb activity will also be measured using the 
Action Research Arm Test (ARAT). The ARAT consists of 
19 items grouped into four subscales: grasp, grip, pinch 
and gross movement. Each subscale is ordered hierarchi-
cally, with a minimum score of 0 and a maximum score 
of 57. ARAT has been recommended as a common data 
element since commencement of this study21 and will 
be collected on all participants post publication of the 
recommendations paper (September 2017). Data will be 
used to model recovery trajectory on the available subset 
only.
Non-motor outcomes: At each time point, we will also 
assess non-motor outcomes which may be used as covari-
ates in subsequent analyses. Sensation will be indexed 
using the light touch portion of the FM-UL assessment, 
cognition using the Montreal Cognitive Assessment, 
fatigue using the Fatigue Assessment Scale, depression 
using Patient Health Questionnaire-9 (PHQ-9).
data analysis and management
Sample size
Statistical power was based on which potential biomark-
er(s) at <2–4 weeks differentiates trajectory of recovery 
at 12 months poststroke. Past data informed our calcu-
lation.22 26 Using R,39 40 we determined the n/group 
necessary to achieve 80% power to detect a stan-
dardised difference in slope between the group defined 
as ‘biomarker positive’ (eg, MEP+) versus ‘biomarker 
negative’ (eg, MEP−) slopes in a multilevel model with 
time nested within participants.41 Given the explor-
atory nature, the analysis plan is flexible, designed to 
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test several different potential biomarkers, and the false 
positive rate is adjusted accordingly, alpha=0.01. For any 
given biomarker, assuming standardised difference in 
slopes is 0.245 between the ‘biomarker positive’ versus 
‘biomarker negative’ groups, 32 subjects/group yields 
80% power for a group by time interaction (alpha=0.01, 
average correlation between time points=0.6). We 
accounted for 10% loss due to death or relocation, 
and 10% inflation for non-compliance; thus, we are 
targeting recruitment of 78 participants.
Data management
All clinical measures will be initially collected on paper 
data forms (and securely stored) and subsequently 
entered into a tailored spreadsheet. All data will be 
confirmed by an independent rater (using the original 
hard copies as a reference) prior to statistical analysis. All 
TMS and MRI data are collected as electronic files that 
will be downloaded from central servers onto local servers 
(and securely stored).
Table 1 Data collected at each assessment
≤7 day, baseline 2-4 weeks 3 months 6 months 12 months
Demographics
  Age: years ✔ ✔ ✔ ✔ ✔
  Sex: male/female/other ✔ ✔ ✔ ✔ ✔
  Premorbid: living, work, mobility ✔ ✔ ✔ ✔ ✔
  Education: years ✗ ✔ ✔ ✔ ✔
  Medical history/comorbidities ✔ ✔ ✔ ✔ ✔
Clinically important recovery
  Fugl-Meyer Upper Limb ✗ ✔ ✔ ✔ ✔
  Motor Assessment Scale item 6, item 7 and 
item 8
✗ ✔ ✔ ✔ ✔
  Rating of Everyday Arm-use in the Community 
and Home
✗ ✔ ✔ ✔ ✔
Brain biomarkers
  Motor-evoked potential (rest and active) ✗ ✔ ✔ ✔ ✔
  MRI: T1, T2 FLAIR, diffusion tensor imaging, 
resting state functional MRI
✗ ✔ ✔ ✔ ✔
  Stroke details
  Modified Rankin Scale ✗ ✔ ✔ ✔ ✔
  National Institute of Health Stroke Scale ✔ ✔ ✔ ✔ ✔
  Lesion location ✔ ✗ ✗ ✗ ✗
  Lesion side, left/right ✔ ✗ ✗ ✗ ✗
  Lesion type, ischaemic/haemorrhagic ✔ ✗ ✗ ✗ ✗
  Acute medical/interventionalist use ✔ ✗ ✗ ✗ ✗
Other measures
  Shoulder abduction and finger extension ✔ ✔ ✔ ✔ ✔
  Action Research Arm Test ✗ ✔ ✔ ✔ ✔
  Accelerometry, ratio affected/unaffected hours 
of use
✗ ✔ ✔ ✔ ✔
  Canadian Occupational Performance Scale ✗ ✔ ✔ ✔ ✔
  Global Rating of Change Scale ✗ ✔ ✔ ✔ ✔
  Sensation, present/impaired/absent ✗ ✔ ✔ ✔ ✔
  Independent walking, yes/no ✗ ✔ ✔ ✔ ✔
  Montreal Cognitive Assessment ✗ ✔ ✔ ✔ ✔
  Fatigue scale ✗ ✔ ✔ ✔ ✔
  Stroke Impact Scale ✗ ✔ ✔ ✔ ✔
  EQ-5D-3L ✗ ✔ ✔ ✔ ✔
  PHQ9 ✗ ✔ ✔ ✔ ✔
EQ-5D-3L, EuroQol five dimension three level; FLAIR, FLuid-Attenuated Inversion Recovery; PHQ-9, Patient Health Questionnaire-9. 
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Identify biomarker(s) of brain structure and/or function
We will use a logistic mixed-effects regression to 
model the probability of attaining clinically important 
change as a function of time and biomarker/s. Time 
will be modelled as the precise number of days post-
stroke for each person. The primary biomarkers of 
interest, informed by the literature, include time 
point 1 MEP status, CST FA AI and CC regional FA. In 
secondary analyses, we will combine sets of biomarkers 
to determine if we can better discriminate clinically 
important recovery achievement. To accommodate 
multiple comparisons, alpha=0.01 will indicate signif-
icance. We will control for age, sex, stroke severity 
(NIHSS) and baseline SAFE score.
Secondary aims
Describe from the stroke survivor’s perspective what is meaningful 
recovery and when it is achieved
We will explore alignment between achievement of 
clinically meaningful recovery (yes/no, per proposed 
metric) and stroke survivor’s own perception of 
recovery; all of which are collected at every time point 
of this study. Using mixed-effect regression, we will 
model the relationship between participants’ percep-
tions of their recovery (as the dependent variable) 
and clinical measures of motor function (eg, FM-UL, 
MAS6, REACH, SIS, EQ-5D), controlling for static 
variables (eg, age at stroke admission, sex). Similarly, 
we will model the relationship between perceptions 
of recovery and more ecological measures of use (eg, 
accelerometry-based measures of use and use asym-
metry), controlling for the same covariates.
Characterise the trajectory of motor recovery, and brain structure and 
function
A multilevel analysis with time nested within participants 
using linear mixed-effect regression modelling will be 
run for each a priori measure of recovery (eg, FM-UL, 
MAS6, REACH, SIS, EQ-5D), brain structure (eg, CST 
FA AI) and function (eg, MEP status). These analyses 
will treat each outcome continuously and control for 
the same covariates as our primary analyses. A major 
goal of these exploratory analyses is to identify the 
best approach to model recovery over time (eg, curvi-
linear models vs truly non-linear models, like a negative 
exponential function) and identify the biomarkers that 
explain the most variance in these trajectories at each 
of the time points investigated. This approach will allow 
us to explore both early and late recovery phases.
EthICs And dIssEMInAtIon
This study is registered at  clinicaltrials. gov 
(NCT02464085). The Strengthening the Reporting of 
Observational Studies in Epidemiology statement will 
guide study conduct and reporting.42 The results of this 
study will be disseminated via peer-reviewed journals; 
local, national and international meetings and confer-
ences; and investigator/institutional websites and asso-
ciated media departments.
PAtIEnt And PublIC InvolvEMEnt
Patients and public were not involved in the study.
dIsCussIon
Our study evaluates clinical and brain measures, and 
will provide the most comprehensive characterisation 
of the long-term trajectory of motor recovery in the 
subgroup of individuals with severe upper limb paresis 
early after stroke. This study has the potential to iden-
tify potential biomarkers that explain who will show 
clinically important recovery, as well as demonstrate 
how this relates to the stroke survivor’s own perception 
of recovery. Identifying biomarkers that are reliably 
associated with meaningful recovery will inform indi-
vidualised treatment decisions, stratification for future 
clinical trials and identification of novel treatment 
targets.
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